Conatus Pharmaceuticals Inc. Release: Caspase Inhibitor Enters Clinical Trial in Islet Transplantation as Treatment for Diabetes
7/20/2012 9:33:24 AM
More...
|
Conatus Pharmaceuticals Inc. Appoints Daniel Ripley as Head of Corporate Development
7/18/2012 10:01:51 AM
More...
|
Conatus Pharmaceuticals Inc. Appoints Mark F. Morris as Head of Biostatistics
7/12/2012 10:14:06 AM
More...
|
Conatus Pharmaceuticals Inc. Appoints Dr.Gary Burgess as Senior Vice President and Chief Medical Officer
11/1/2011 11:18:24 AM
More...
|
Conatus Pharmaceuticals Inc.Terminates Phase 2 Clinical Trial of CTS-1027
10/26/2011 6:15:46 AM
More...
|
Conatus Pharmaceuticals Inc.Announces CTP-499 Data Presentations at the American Society of Nephrology (ASN) Kidney Week Meeting
10/19/2011 10:43:11 AM
More...
|
Conatus Pharmaceuticals Inc. Completes the Second Closing of its Series B Private Placement Financing
4/13/2011 7:17:53 AM
More...
|
Conatus Pharmaceuticals Inc. Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
4/1/2011 7:20:00 AM
More...
|
Conatus Pharmaceuticals Inc. Will Display HCV Clinical Trial Data at the International Liver Congress(TM) (EASL) in March
3/14/2011 8:10:39 AM
More...
|
Conatus Pharmaceuticals Inc. Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
2/17/2011 11:08:19 AM
More...
|
|